Moderna, Inc. (MRNA) and Merck & Co Inc. (MRK) on Tuesday reported median five-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, evaluating intismeran autogene, an investigational personalized cancer vaccine, in combination with Merck's Keytruda in patients with high-risk melanoma following complete resection.
The analysis showed that adjuvant treatment with intismeran autogene plus Keytruda continued to demonstrate a clinically meaningful improvement in recurrence-free survival, reducing the risk of recurrence or death by 49% compared with Keytruda alone.
"These five-year follow up data are encouraging and we look forward to late-stage data from the INTerpath clinical development program with Moderna, across a range of tumor types where significant unmet needs remain," said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories.
On Friday, Moderna shares rose 6.31% to $41.84, while Merck shares fell 1.93% to $108.83.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.